GENEVA—The use of combinations including checkpoint inhibition with other immunotherapies, other targeted therapies and chemotherapy was discussed at the European Lung Cancer Conference by Martin Reck MD PhD from the department of thoracic oncology at the Lung Clinic Grosshansdorf near Hamburg, Germany. He gave Oncology Times reporter Peter Goodwin his views about their potential impact on daily oncology practice.
You may also like...
Colorectal cancer screening: survey of 11 European countries finds big mortality benefit 6 Nov, 2013 Targeting Emerging Drugable Pathways in Breast Cancer—Clinical Potential Assessed 28 Mar, 2015 Higher Radiation Dose Improved Survival in Children with Ependymoma 12 May, 2015 Low Cost Screening Could Halve Stillbirths Due To Syphilis 20 Jul, 2011
- Previous story Immunotherapy: Standard of Care in Waiting for Non Small-Cell Lung Cancer
- Next story Prior Chemotherapy: No Bar to Checkpoint Inhibition in Mesothelioma
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014